EUVIMEDEUVIMED entdecken
Crossref

Development of pH-Resilient Boronic Acid ENPP1 Inhibitors for STING-Mediated Cancer Immunotherapy

Ya-Ling Li, Mei-Ling He, Jing-Dong Zhang, Ting Shi, Shuang He, Zi-Qiang Chen, Chao-Wen Yang, Xiao-Mei Chen, Shuai Wang iD, You-Cai Xiao iD, Fen-Er Chen iD

Journal of Medicinal Chemistry · 22.10.2026 · 69 (20) · 24096-24120

DOI: 10.1021/acs.jmedchem.6c01649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.10.2026. Verfasst von Ya-Ling Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases, Pyrophosphatases, Boronic Acids, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Tianfu Jincheng Laboratory, Sichuan University, Department of Science and Technology of Sichuan Province, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital Mianyang Central Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) hydrolyzes cGAMP within the tumor microenvironment (TME), suppressing stimulator of interferon genes (STING)-mediated antitumor immunity. Inspired by the phosphate-based inhibitor STF-1084, we developed a novel class of non-nucleotide ENPP1 inhibitors featuring a boronic acid zinc-binding group (ZBG), which led to the identification of the potent and pH-resilient compound 36. In vitro evaluations confirmed that compound 36 enhances cGAMP-mediated STING activation, driving the upregulation of key immune effectors and chemokines. Furthermore, in a syngeneic CT26 tumor model, monotherapy with compound 36 (20 mg/kg, IP) achieved a tumor growth inhibition (TGI) of 57.4%. Notably, combination therapy with a single dose of oxaliplatin (OX) exhibited a synergistic antitumor effect (TGI = 80.7%) without observable toxicity. Collectively, this study identifies compound 36 as a promising lead ENPP1 inhibitor and further highlights boronic acid as an effective ZBG for the development of ENPP1-targeted cancer immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoric Diester HydrolasesPyrophosphatasesBoronic AcidsImmunotherapyAntineoplastic AgentsMembrane ProteinsEnzyme InhibitorsNeoplasmsAnimalsHumansMiceSTING ProteinHydrogen-Ion ConcentrationcGAS-STING Signaling PathwayCell Line, Tumor

Stichwörter der Autor:innen

cGAMPENPP1antitumorboronic acidcGAS-STINGimmune systempathway

Substanzen

Phosphoric Diester HydrolasesPyrophosphatasesBoronic Acidsectonucleotide pyrophosphatase phosphodiesterase 1STING ProteinAntineoplastic AgentsMembrane ProteinsEnzyme InhibitorsSTING1 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu…
  • College of Pharmacy, Jiangxi Normal University, Nanchang, Jiangxi330022, China.
  • Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai200433, China.
  • Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang330022, China.

ORCID-Profile: Shuai Wang, You-Cai Xiao, Fen-Er Chen

Förderung

  • Tianfu Jincheng Laboratory, Sichuan University
  • Department of Science and Technology of Sichuan Province
  • National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital Mianyang Central Hospital

Zitieren

APA

Li, Y. L., He, M. L., Zhang, J. D., Shi, T., He, S., Chen, Z. Q., Yang, C. W., Chen, X. M., Wang, S., Xiao, Y. C., & Chen, F. E. (2026). Development of pH-Resilient Boronic Acid ENPP1 Inhibitors for STING-Mediated Cancer Immunotherapy. Journal of Medicinal Chemistry, 69(20), 24096-24120. https://doi.org/10.1021/acs.jmedchem.6c01649

Vancouver

Li YL, He ML, Zhang JD, Shi T, He S, Chen ZQ, et al. Development of pH-Resilient Boronic Acid ENPP1 Inhibitors for STING-Mediated Cancer Immunotherapy. Journal of Medicinal Chemistry. 2026;69(20):24096-24120. doi:10.1021/acs.jmedchem.6c01649

BibTeX
@article{Li2026,
  author = {Li, Ya-Ling and He, Mei-Ling and Zhang, Jing-Dong and Shi, Ting and He, Shuang and Chen, Zi-Qiang and Yang, Chao-Wen and Chen, Xiao-Mei and Wang, Shuai and Xiao, You-Cai and Chen, Fen-Er},
  title = {Development of pH-Resilient Boronic Acid ENPP1 Inhibitors for STING-Mediated Cancer Immunotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {20},
  pages = {24096--24120},
  doi = {10.1021/acs.jmedchem.6c01649}
}
Kostenlos starten →